Hospital Universitario 12 de Octubre
Email: info@stabtherapeutics.com
Dirección: Calle Ferraz 78, 2º A, 28008 Madrid, España
STAb Therapeutics is a spin-off company from the Research Institute Hospital 12 de Octubre (imas12), which focuses on developing next-generation immune redirection strategies for solid and hematological tumors. The company’s strategy involves a T cell redirecting approach that combines principles of adoptive cell therapy and bispecific antibodies. This approach is based on the in vivo production of T cell-engagers (TCE) by engineered cells, which results in effective serum concentrations of TCE, expansion and persistence of adoptively transferred STAb – T cells, and polyclonal recruitment of both modified and unmodified bystander T cells present at the tumor microenvironment.